Search results
Results from the WOW.Com Content Network
cBio Cancer Genomics Portal →: Memorial Sloan-Kettering Cancer Center, United States Copy number, Mutation, Methylation, Gene Expression, miRNA Expression, Protein, Phosphorylation: No Yes Human: No Yes No International Cancer Genome Consortium →: Worldwide: Mutation: Yes Yes Human: No Yes Yes Integrative Oncogenomics Cancer Browser ...
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
The Network of Cancer Genes (NCG) is a freely accessible web resource of genes that, when altered in their sequence, drive clonal expansion of normal tissues (healthy drivers) or cancer (cancer drivers). The project was launched in 2010 and has reached its 7th release in 2022.
This is a list of countries by cancer frequency, as measured by the number of new cancer cases per 100,000 population among countries, based on the 2018 GLOBOCAN statistics and including all cancer types (some earlier statistics excluded non-melanoma skin cancer).
The following is a list of chemicals published as a requirement of Safe Drinking Water and Toxic Enforcement Act of 1986, commonly known as California Proposition 65, that are "known to the state to cause cancer or reproductive toxicity" as of January 3, 2020. [1]
IARC group 2B substances, mixtures and exposure circumstances are those that have been classified as "possibly carcinogenic to humans" by the International Agency for Research on Cancer (IARC) as [1] This category is used when there is limited evidence of carcinogenicity in humans and less than sufficient evidence of carcinogenicity in experimental animals.
Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer. [17] In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies". [18]